0001295345-12-000060.txt : 20120521 0001295345-12-000060.hdr.sgml : 20120521 20120521125420 ACCESSION NUMBER: 0001295345-12-000060 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 9 CONFORMED PERIOD OF REPORT: 20120331 FILED AS OF DATE: 20120521 DATE AS OF CHANGE: 20120521 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AMERICAN BIOGENETIC SCIENCES INC CENTRAL INDEX KEY: 0000856984 STANDARD INDUSTRIAL CLASSIFICATION: BLANK CHECKS [6770] IRS NUMBER: 112655906 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-19041 FILM NUMBER: 12857658 BUSINESS ADDRESS: STREET 1: 40 WALL STREET STREET 2: 28TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10005 BUSINESS PHONE: 212 4007198 MAIL ADDRESS: STREET 1: 40 WALL STREET STREET 2: 28TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10005 10-Q 1 maba03312012.htm QUARTERLY REPORT FOR THE PERIOD ENDED MARCH 31, 2012 maba

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________

FORM 10-Q
________________________________

ý                                  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2012

 

or

 

¨                                  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

  

For the transition period from    to

 

Commission file number 0-19041

 

AMERICAN BIOGENETIC SCIENCES, INC.
(Exact Name Of Registrant As Specified In Its Charter)

Delaware 11-2655906
(State of Incorporation) (I.R.S. Employer Identification No.)
       
40 Wall Street, 28th Floor 10005
(Address of Principal Executive Offices) (ZIP Code)

Registrant's Telephone Number, Including Area Code: (212) 400-7198

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes x  No ¨

On March 31, 2012, the Registrant had 1,088,740 shares of common stock outstanding.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company (as defined in Rule 12b-2 of the Exchange Act).

Large accelerated filer ¨ Accelerated filer ¨  Non-Accelerated filer ¨  Smaller reporting company x


 

TABLE OF CONTENTS

Item
 Description
 Page

PART I - FINANCIAL INFORMATION
 

ITEM 1.

           3   

ITEM 2.

           8    
ITEM 3.    QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK. 9

ITEM 4.

           9    
 

PART II - OTHER INFORMATION
 

ITEM 1.

           9   
ITEM 1A.    RISK FACTORS. 9

ITEM 2.

           9    

ITEM 3.

           9    

ITEM 4.

           9    

ITEM 5.

           9    
ITEM 6.    EXHIBITS. 9

 


PART I - FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS Back to Table of Contents

    Balance Sheets - March 31, 2012 (Unaudited) and December 31, 2011 3
    Statements of Operations - Three Months Ended March 31, 2012 and 2011 (Unaudited) 4
    Statements of Cash Flows - Three Months Ended March 31, 2012 and 2011 (Unaudited) 5
Notes to Financial Statements 6

 

American Biogenetic Sciences, Inc.
Balance Sheets Back to Table of Contents
 
March 31, 2012 December 31, 2011
  (Unaudited)  

ASSETS
 
    Total Assets $ 0 $ 0
 

LIABILITIES AND STOCKHOLDERS' DEFICIT
Current Liabilities:
   Accounts payable - trade $ 10,068 $ 7,568
   Accrued interest expenses 22,800 20,520
   Convertible note, related party 76,000 76,000
   Advances from and accruals due to related party 143,113 129,113
         Total current liabilities 251,981 233,201
 
         Total liabilities 251,981 233,201
 
Stockholders' Deficit:
 
Preferred stock, 10,000,000 shares authorized, $0.0001 par value;
     none issued and outstanding - -
Common stock, 900,000,000 shares authorized, $0.0001 par value;
     1,088,740 shares issued and outstanding 109 109
   Additional paid-in capital 46,191 46,191
   Accumulated deficit (298,281) (279,501)
     Total Stockholders' deficit (251,981) (233,201)
 
       Total Liabilities and Stockholders' Deficit $ 0 $ 0
 

See notes to unaudited interim financial statements.


American Biogenetic Sciences, Inc.
Statements of Operations

Back to Table of Contents
Three Months Three Months
Ended Ended
March 31, 2012 March 31, 2011
(Unaudited) (Unaudited)
 
Revenue $ 0 $ 0
 
Costs and Expenses:
   General and administrative 16,500 23,102
   Interest expense 2,280 2,280
Total costs and expenses 18,780 25,382
 
Net loss $ (18,780) $ (25,382)
 
Basic and diluted per shares amounts:
   Basic and diluted net loss $ (0.02) $ (0.02)
 
Weighted average shares outstanding:
Basic and diluted 1,088,740 1,088,740
 

See notes to unaudited interim financial statements.


American Biogenetic Sciences, Inc.

Statements of Cash Flows
  Back to Table of Contents
Three Months Three Months
Ended Ended
                March 31, 2012 March 31, 2011
  (Unaudited) (Unaudited)
Cash flows from operating activities:
Net loss $ (18,780) (25,382)
Adjustment required to reconcile net loss to cash used in operating activities:
   Fair value of expenses provided from related parties 14,000 19,000
   Increase in accounts payable and accrued expenses 4,780 6,382
    Cash flows used in operating activities $ 0 0
 
Cash flows from investing activities:
     Cash used in investing activities 0 0
  
Cash flows from financing activities:
   Proceeds from the issuance of common stock 0 0
   Advances from related parties 0 0
     Cash provided by financing activities 0 0
 
     Change in cash 0 0
Cash - beginning of period 0 0
Cash - end of period $ 0 $ 0
 

See notes to unaudited interim financial statements.


AMERICAN BIOGENETIC SCIENCES, INC.
Notes to Unaudited Interim Financial Statements
March 31, 2012
Back to Table of Contents

Note 1. The Company

American Biogenetic Sciences, Inc. (the "Company", “We” or "ABS") was incorporated in Delaware on September 1, 1983. Prior to ceasing its operations in 2002, the Company was engaged in the research, development and production of bio-pharmaceutical products. On September 19, 2002, the Registrant filed for bankruptcy under the U.S. Bankruptcy Code in the U.S. Bankruptcy Court Eastern District of New York. On November 4, 2005, the Company emerged from Bankruptcy Court.

Note 2. Going Concern

The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred losses, has negative operational cash flows and has no revenues. The future of the Company is dependent upon Management success in its efforts and limited resources to pursue and effect a business combination. These conditions raise substantial doubt about the Company's ability to continue as a going concern. These financial statements do not include any adjustments that might arise from this uncertainty.

Note 3. Basis of Presentation

The Financial Statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America. In the opinion of management, the accompanying unaudited financial statements include all adjustments, consisting of only normal recurring accruals, necessary for a fair statement of financial position, results of operations, and cash flows. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the financial statements and the accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2011. The accounting policies are described in the “Notes to the Financial Statements” in the 2011 Annual Report on Form 10-K and updated, as necessary, in this Form 10-Q. The year-end balance sheet data presented for comparative purposes was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States. The results of operations for the three months ended March 31, 2012 are not necessarily indicative of the operating results for the full year or for any other subsequent interim period.

Accounting Policies

Use of Estimates: The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from the estimates.

Cash and Cash Equivalents: For financial statement presentation purposes, the Company considers those short-term, highly liquid investments with original maturities of three months or less to be cash or cash equivalents.

Fair Value of Financial Instruments: ASC # 825, "Disclosures about Fair Value of Financial Instruments," requires disclosure of fair value information about financial instruments. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of March 31, 2012. These financial instruments include accounts payable and accrued expenses. Fair values were assumed to approximate carrying values for these financial instruments since they are short-term in nature and their carrying amounts approximate fair values.

Earnings per Common Share: Basic net loss per share is computed using the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed using the weighted average number of common and dilutive equivalent shares outstanding during the period. Dilutive common equivalent shares consist of options to purchase common stock (only if those options are exercisable and at prices below the average share price for the period) and shares issuable upon the conversion of issued and outstanding preferred stock. Due to the net losses reported, dilutive common equivalent shares were excluded from the computation of diluted loss per share, as inclusion would be anti-dilutive for the periods presented. There were no common equivalent shares required to be added to the basic weighted average shares outstanding to arrive at diluted weighted average shares outstanding as of March 31, 2012 or 2011.

Income Taxes: The Company accounts for income taxes in accordance with ASC # 740, "Accounting for Income Taxes," which requires recognition of estimated income taxes payable or refundable on income tax returns for the current year and for the estimated future tax effect attributable to temporary differences and carry-forwards. Measurement of deferred income tax is based on enacted tax laws including tax rates, with the measurement of deferred income tax assets being reduced by available tax benefits not expected to be realized.

FIN 48 requires that the Company recognize in its financial statements the impact of a tax position, if that position is more likely than not of being sustained on audit, based on the technical merits of the position. Management of the Company is not aware of any additional needed liability for unrecognized tax benefits at March 31, 2012 and 2011.

Impact of recently issued accounting standards

There were no new accounting pronouncements that had a significant impact on the Company’s operating results or financial position.

Note 4. Convertible Notes to Related Party

In October 2009, we issued a convertible promissory note in the amount of $76,000. The note bears interests of 12% per annum until paid or converted. Interest is payable upon the maturity date. The conversion rate is $0.001 per share. The note was issued in consideration of cash advances made and for services provided to the Company by our President.

In accordance Accounting Standard Codification ( “ASC # 815”), Accounting for Derivative Instruments and Hedging Activities, we evaluated the holder’s non-detachable conversion right provision and liquidated damages clause, contained in the terms governing the note to determine whether the features qualify as an embedded derivative instruments at issuance. Such non-detachable conversion right provision and liquidated damages clause did not need to be accounted as derivative financial instruments.

Note 5. Related Party Transactions

Fair value of services: Our President provides services to the Company, which services are accrued and are valued at $2,000 per month. The total of these accrued expenses for the period ended March 31, 2012 was $6,000 and is reflected in the statement of operations as general and administrative expenses.

An entity controlled by the Company’s President provided office space to the Company valued at $1,000 per month. The total of $3,000 during the three months ended March 31, 2012 was recorded as accrued expenses and is reflected in the statement of operations as general and administrative expenses.

An entity controlled by the Company’s President provided corporate securities compliance services to the Company valued at $5,000 during the period ended March 31, 2012, which was recorded as accrued expenses and is reflected in the statement of operations as general and administrative expenses.

Due Related Parties: Amounts due to related parties consist of fair value of services provided by our President, accrued office space expenses, corporate regulatory compliance expenses and cash advances received from our President and control shareholder. Such items due totaled $143,113 at March 31, 2012 and $129,113 at December 31, 2011.

Note 6. Commitments and Contingencies

There are no pending or threatened legal proceedings as of March 31, 2012. The Company has no non-cancellable operating leases.


ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS AND PLAN OF OPERATIONS Back to Table of Contents

Some of the statements contained in this quarterly report of American Biogenetic Sciences, Inc., a Delaware corporation discuss future expectations, contain projections of our plan of operation or financial condition or state other forward-looking information. Forward-looking statements give our current expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expect," "plan," "anticipate," "believe," "estimate," "continue," or the negative of such terms or other similar expressions.

General Background

American Biogenetic Sciences, Inc., a Delaware corporation, is sometimes referred to herein as "we", "us", "our", "Company" and the "Registrant". The Registrant was formed in 1983 for the purpose of researching, developing and marketing cardiovascular and neurobiology products for commercial development and distributing vaccines. The Registrant's products were designed for in vitro and in vivo diagnostic procedures and therapeutic drugs, and its products had been identified for use in the treatment of epilepsy, migraine and mania, neurodegenerative diseases, coronary artery diseases and cancer. The Registrant commenced selling its products during the last quarter of 1997 but did not generate any sufficient revenues from operations to fund its operating expenses.

On September 19, 2002, the Registrant filed a petition under the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the Eastern District of New York. On November 4, 2005, the Bankruptcy Court approved an order authorizing a change in control and provided that the Company, subsequent to the bankruptcy proceeding, is free and clear of all liens, claims and other obligations.

Plan of Operation

We have no present operations or revenues and our current activities are related to seeking new business opportunities, including seeking an acquisition or merger with an operating company. If our management seeks to acquire another business or pursue a new business opportunity, it would have substantial flexibility in identifying and selecting a prospective business. Registrant would not be obligated nor does management intend to seek pre-approval from our shareholders. Under the laws of the State of Delaware, the consent of holders of a majority of the issued and outstanding shares, acting without a shareholders meeting, can approve an acquisition.

The Registrant is entirely dependent on the judgment of its executive officer/director in connection with pursuing a new business opportunity or a selection process for a target operating company. In evaluating a prospective new business opportunity or an operating company, he would consider, among other factors, the following: (i) costs associated with effecting a transaction; (ii) equity interest in and opportunity to control the prospective candidate; (iii) growth potential of the target business; (iv) experience and skill of management and availability of additional personnel; (v) necessary capital requirements; (vi) the prospective candidate's competitive position; (vii) stage of development of the business opportunity; (viii) the market acceptance of the business, its products or services; (ix) the availability of audited financial statements of the potential business opportunity; and (x) the regulatory environment that may be applicable to any prospective business opportunity.

The foregoing criteria are not intended to be exhaustive and there may be other criteria that management may deem relevant. In connection with an evaluation of a prospective or potential business opportunity, management may be expected to conduct a due diligence review.

Liquidity and Capital Resources

We will use our limited personnel and financial resources in connection with seeking new business opportunities, including seeking an acquisition or merger with an operating company. It may be expected that entering into a new business opportunity or business combination will involve the issuance of a substantial number of restricted shares of common stock. If such additional restricted shares of common stock are issued, our shareholders will experience a dilution in their ownership interest in the Registrant. If a substantial number of restricted shares are issued in connection with a business combination, a change in control may be expected to occur.

On March 31, 2012, we had no assets and had total liabilities of $251,981 consisting of $143,113 in advances from and accruals due to related parties, a short-term note in the amount of $76,000, accrued interest expenses of $22,800 and accounts payable of $10,068.

In connection with our plan to seek new business opportunities and/or effecting a business combination, we may determine to seek to raise funds from the sale of restricted stock or debt securities.We have no agreements to issue any debt or equity securities and cannot predict whether equity or debt financing will become available at terms acceptable to us, if at all.

There are no limitations in our articles of incorporation on our ability to borrow funds or raise funds through the issuance of restricted common stock to effect a business combination. Our limited resources and lack of operating history may make it difficult to do borrow funds or raise capital. Our inability to borrow funds or raise funds through the issuance of restricted common stock required to effect or facilitate a business combination may have a material adverse effect on our financial condition and future prospects, including the ability to complete a business combination. To the extent that debt financing ultimately proves to be available, any borrowing will subject us to various risks traditionally associated with indebtedness, including the risks of interest rate fluctuations and insufficiency of cash flow to pay principal and interest, including debt of an acquired business.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK Back to Table of Contents

We have not entered into, and do not expect to enter into, financial instruments for trading or hedging purposes.

ITEM 4. CONTROLS AND PROCEDURES Back to Table of Contents

Evaluation of disclosure controls and procedures. As of March 31, 2012, the Company's chief executive officer/chief financial officer conducted an evaluation regarding the effectiveness of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) under the Exchange Act. Based upon the evaluation of these controls and procedures, our chief executive officer/chief financial officer concluded that our disclosure controls and procedures were effective as of the date of filing this quarterly report.

Changes in internal controls. During the quarterly period covered by this report, no changes occurred in our internal control over financial reporting that materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS Back to Table of Contents

None.

ITEM 1A. RISK FACTORS Back to Table of Contents

In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, “Item 1. Description of Business, subheading Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2011, which could materially affect our business, financial condition or future results. The risks described in our Annual Report on Form 10-K are not the only risks facing our company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS Back to Table of Contents

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES Back to Table of Contents

None.

ITEM 4. MINE SAFTY DISCLOSURE Back to Table of Contents

None.

ITEM 5. OTHER INFORMATION Back to Table of Contents

None.

ITEM 6. EXHIBITS Back to Table of Contents

(a) The following documents are filed as exhibits to this report on Form 10-Q or incorporated by reference herein. Any document incorporated by reference is identified by a parenthetical reference to the SEC filing that included such document.

Exhibit No.

 Description
31 Certification of CEO/CFO pursuant to Rule 13a-14(a) or 15d-14(a) of the Exchange Act pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32 Certification of CEO/CFO pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the date indicated.

/s/ Richard Rubin
Richard Rubin
   CEO, CFO and Chairman
   Dated: May 21, 2012

 EX-31 2 exh31.htm EXHIBIT 31 Exhibit 31

CERTIFICATIONS

I, Richard Rubin, certify that:

1. I have reviewed this quarterly report of American Biogenetic Sciences, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the  issuer as of, and for, the periods presented in this report;

4. The  issuer's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as 4efined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the  issuer and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the  issuer, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the  issuer's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the  issuer's internal control over financial reporting that occurred during the  issuer's most recent fiscal quarter (the  issuer's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the   issuer's internal control over financial reporting; and

5. The  issuer's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the   issuer's auditors and the audit committee of the  issuer's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the  issuer's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether r not material, that involves management or other employees who have a significant role in the  issuer's internal control over financial reporting.

Date: May 21, 2012

/s/ Richard Rubin
CEO, CFO and Chairman

 EX-32 3 exh32.htm EXHIBIT 32 Exhibit 32

Exhibit 32

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of American Biogenetic Sciences, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2012 (the “Report”), as filed with the Securities and Exchange Commission on the date hereof, I, Richard Rubin, CEO and CFO of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Richard Rubin
CEO, CFO and Chairman

Dated: May 21, 2012

A signed original of this written statement required by Section 906 has been provided to American Biogenetic Sciences, Inc. and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 EX-101.INS 4 maba-20120331.xml 10-Q 2012-03-31 false American Biogenetic Sciences Inc. 0000856984 --12-31 Smaller Reporting Company Yes No No 2012 Q1 0 0 0 0 0 0 10068 7568 22800 20520 76000 76000 143113 129113 251981 233201 109 109 46191 46191 -298281 -279501 -251981 -233201 0 0 0 0 16500 23102 2280 2280 18780 25382 -18780 -25382 -0.02 -0.02 1088740 1088740 -18780 -25382 0 0 14000 19000 4780 6382 0 0 0 0 0 0 0 0 0 0 0 0 0 0 <!--egx--><p><b>Note 1. The Company</b></p> <p>American Biogenetic Sciences, Inc. (the "Company", &#147;We&#148; or "ABS") was incorporated in Delaware on September 1, 1983. Prior to ceasing its operations in 2002, the Company was engaged in the research, development and production of bio-pharmaceutical products. On September 19, 2002, the Registrant filed for bankruptcy under the U.S. Bankruptcy Code in the U.S. Bankruptcy Court Eastern District of New York. On November 4, 2005, the Company emerged from Bankruptcy Court.</p> <!--egx--><p><b>Note 2. Going Concern </b></p> <p>The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred losses, has negative operational cash flows and has no revenues. The future of the Company is dependent upon Management success in its efforts and limited resources to pursue and effect a business combination. These conditions raise substantial doubt about the Company's ability to continue as a going concern. These financial statements do not include any adjustments that might arise from this uncertainty.</p> <!--egx--><p><b>Note 3. Basis of Presentation</b></p> <p>The Financial Statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America. In the opinion of management, the accompanying unaudited financial statements include all adjustments, consisting of only normal recurring accruals, necessary for a fair statement of financial position, results of operations, and cash flows. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the financial statements and the accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2011. The accounting policies are described in the &#147;Notes to the Financial Statements&#148; in the 2011 Annual Report on Form 10-K and updated, as necessary, in this Form 10-Q. The year-end balance sheet data presented for comparative purposes was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States. The results of operations for the three months ended March 31, 2012 are not necessarily indicative of the operating results for the full year or for any other subsequent interim period.</p> <p><b>Accounting Policies</b></p> <p><i>Use of Estimates:</i> The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from the estimates.</p> <p><i>Cash and Cash Equivalents:</i> For financial statement presentation purposes, the Company considers those short-term, highly liquid investments with original maturities of three months or less to be cash or cash equivalents.</p> <p><i>Fair Value of Financial Instruments:</i> ASC # 825, <em>"Disclosures about Fair Value of Financial Instruments,"</em> requires disclosure of fair value information about financial instruments. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of March 31, 2012. These financial instruments include accounts payable and accrued expenses. Fair values were assumed to approximate carrying values for these financial instruments since they are short-term in nature and their carrying amounts approximate fair values.</p> <p><i>Earnings per Common Share:</i> Basic net loss per share is computed using the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed using the weighted average number of common and dilutive equivalent shares outstanding during the period. Dilutive common equivalent shares consist of options to purchase common stock (only if those options are exercisable and at prices below the average share price for the period) and shares issuable upon the conversion of issued and outstanding preferred stock. Due to the net losses reported, dilutive common equivalent shares were excluded from the computation of diluted loss per share, as inclusion would be anti-dilutive for the periods presented. There were no common equivalent shares required to be added to the basic weighted average shares outstanding to arrive at diluted weighted average shares outstanding as of March 31, 2012 or 2011.</p> <p><i>Income Taxes:</i> The Company accounts for income taxes in accordance with ASC # 740, <em>"Accounting for Income Taxes,"</em> which requires recognition of estimated income taxes payable or refundable on income tax returns for the current year and for the estimated future tax effect attributable to temporary differences and carry-forwards. Measurement of deferred income tax is based on enacted tax laws including tax rates, with the measurement of deferred income tax assets being reduced by available tax benefits not expected to be realized.</p> <p>FIN 48 requires that the Company recognize in its financial statements the impact of a tax position, if that position is more likely than not of being sustained on audit, based on the technical merits of the position. Management of the Company is not aware of any additional needed liability for unrecognized tax benefits at March 31, 2012 and 2011.</p> <p><strong><i>Impact of recently issued accounting standards </i></strong></p> <p>There were no new accounting pronouncements that had a significant impact on the Company&#146;s operating results or financial position. </p> <!--egx--><p><b>Note 4. Convertible Notes to Related Party</b></p> <p>In October 2009, we issued a convertible promissory note in the amount of $76,000. The note bears interests of 12%&nbsp;per annum until paid or converted. Interest is payable upon the maturity date. The conversion rate is $0.001 per share. The note was issued in consideration of cash advances made and for services provided to the Company by our President. </p> <p>In accordance Accounting Standard Codification ( &#147;ASC # 815&#148;), <i>Accounting for Derivative Instruments and Hedging Activities</i>, we evaluated the holder&#146;s non-detachable conversion right provision and liquidated damages clause, contained in the terms governing the note to determine whether the features qualify as an embedded derivative instruments at issuance. Such non-detachable conversion right provision and liquidated damages clause did not need to be accounted as derivative financial instruments. </p> <!--egx--><p><b>Note 5. Related Party Transactions</b></p> <p><i>Fair value of services: </i>Our President provides services to the Company, which services are accrued and are valued at $2,000 per month. The total of these accrued expenses for the period ended March 31, 2012 was $6,000 and is reflected in the statement of operations as general and administrative expenses. </p> <p>An entity controlled by the Company&#146;s President provided office space to the Company valued at $1,000 per month. The total of $3,000 during the three months ended March 31, 2012 was recorded as accrued expenses and is reflected in the statement of operations as general and administrative expenses.</p> <p>An entity controlled by the Company&#146;s President provided corporate securities compliance services to the Company valued at $5,000 during the period ended March 31, 2012, which was recorded as accrued expenses and is reflected in the statement of operations as general and administrative expenses.</p> <p><i>Due Related Parties: </i>Amounts due to related parties consist of fair value of services provided by our President, accrued office space expenses, corporate regulatory compliance expenses and cash advances received from our President and control shareholder. Such items due totaled $143,113 at March 31, 2012 and $129,113 at December 31, 2011.</p> <!--egx--><p><b>Note 6. Commitments and Contingencies</b></p> <p>There are no pending or threatened legal proceedings as of March 31, 2012. The Company has no non-cancellable operating leases.</p> 65748 1088740 0000856984 2012-01-01 2012-03-31 0000856984 2012-03-31 0000856984 2010-12-31 0000856984 2011-01-01 2011-03-31 0000856984 2011-12-31 0000856984 2011-03-31 iso4217:USD shares $0.0001 par value; 10,000,000 shares authorized; none issued $0.0001 par value; 100,000,000 shares authorized; 1,088,740 issued and outstanding at March 31, 2012 and December 31, 2010 EX-101.SCH 5 maba-20120331.xsd 000040 - Statement - American Biogenetic Sciences, Inc. - Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 000010 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 000020 - Statement - American Biogenetic Sciences, Inc. - Balance Sheets link:presentationLink link:definitionLink link:calculationLink 000050 - Disclosure - Notes to Unaudited Interim Financial Statements link:presentationLink link:definitionLink link:calculationLink 000030 - Statement - American Biogenetic Sciences, Inc. - Statements of Operations link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 6 maba-20120331_cal.xml EX-101.DEF 7 maba-20120331_def.xml EX-101.LAB 8 maba-20120331_lab.xml Statements of Cash Flows Weighted average shares outstanding Total current liabilities Convertible note, related party Statement [Line Items] Entity Voluntary Filers Basic and diluted net loss Accrued interest expenses Total current assets Entity Registrant Name Fair value of services provided by related parties Net loss Interest expenses Document Period End Date Cash - end of period Cash - end of period Cash Current Fiscal Year End Date Amendment Flag Note to Unaudited Interim Financial Statements Revenue Total Stockholders' Deficiency Common stock Entity Current Reporting Status Note 1. The Company Cash flows from operating activities: Basic and diluted Current Liabilities: Current assets: Entity Central Index Key Note 4. Convertible Notes to Related Party Note 3. Basis of Presentation Increase (decrease) in accounts payable and accrued expenses General and administrative Advances from and accruals due to related party Note 5. Related Party Transactions Cash - beginning of period Cash - beginning of period (Increase) decrease in current assets Additional paid in capital Accounts payable - trade LIABILITIES AND STOCKHOLDERS' DEFICIENCY Document Fiscal Year Focus Cash flows from financing activities: Statements of Operations Total Liabilities and Stockholders' Deficiency Entity Filer Category Cash used in investing activities Expenses paid by issuance of common stock Costs and expenses: Cash flows used by operating activities NET LOSS Total Assets Document Fiscal Period Focus Entity Common Stock, Shares Outstanding Change in cash Adjustments to reconcile net loss to cash used in operating activities: ASSETS Entity Well-known Seasoned Issuer Note 2. Going Concern Basic and diluted per share amounts: Preferred stock Entity Public Float Balance Sheets Document Type Cash generated by financing activities Total costs and expenses Stockholders' deficiency: Statement [Table] Note 6. Commitments and Contingencies Procceds from related party borrowings Cash flows from investing activities: Accumulated deficit Document and Entity Information EX-101.PRE 9 maba-20120331_pre.xml ZIP 10 0001295345-12-000060-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001295345-12-000060-xbrl.zip M4$L#!!0````(`,UFM4"AR=C@I!0``(Y9```1`!P`;6%B82TR,#$R,#,S,2YX M;6Q55`D``T)SND]"<[I/=7@+``$$)0X```0Y`0``U3S;6.(91_%D!$? MWA2/4_%VR\C)-$.JZ=DX%\.W6RB^KA==[\&D6VR;X(#DWYSKI)P(57R"Y2S1 MJA`/Q4=<]3GN_Q9O_11'W=].MF=GSBW_('*ITPN5GO.B%0[B[T8[P)\FM,;" M"NPI#*4X?)GQ41NX(<^,L)`:-',9*FR+DJKOFDE2Y8G[M'QWNAE!G M%E9@S\H\QVU)D_#LL^#Y$O9VN\!>S]M%"V<(OI29R,_@^4CGK>3>3G@&4]A' M,=5Y`S^2;`+%L[92"V/2WC22B]:2=,^ M9A8M`&JM:"'8W^(VH,$B`NM?U64UUHY37PO^4!FLI#"W-R+])/^*#)P MX.D'GH/KU0HRVT("GZYU(=9GP\%^Y-FP(YGIRJE&0" MB,Y+T02P/E?CW9TXWG&B7A7+"],US[JX?[0A5=XT`SYOZM'[>_'185Q;^SS( MYV!L,;J='8C3*^/[`$FX@,?I;:&3+W_G62D8E$-O%%98!=CLU@Q^F;[=NRKC_5%>W@0XIJ%MSFRUGWM[1SV5T1V+8HKE>B)>*^-.;WC,J-*4@=AWMGM M.VYDLO;&NS,[7Q/?5Z.UC6_=&<9M0BLZ0/H%##^760D!$<`@@&7>=`'OHAX: MX1*0ST+9RH*-4:Z_O3@Z/#S8C5JQ;8BF;4NKH;F^^/3^YO:VW]]8PQM0UH2[ M3!O;X7ICQKSTW2-V9K%(O1D&NKF^1-PN5H']WHQ;HZF[52UD'S\L3UZKA1\\C#IQ<+K@1Y\+^?Z5F M&HN^[2'251IZ[1S_.[0?;?3`5F36IT MFD#N)#=31,?#%4"_&!E+#'15,H*(BDMJE<1U5^I*W4'BU5CWG"I@=2Q?@[@G M*HDUB4,NP]PD$2EU(,..XSN=Y_H>R^]-U>AIR"]%Q!(E6H,(Y)RM10IDW:54 M$!!>SJ*>`/UB9#QA42N3,>9J)+`K9<8[FV^\`643X,NVLP`X_'PG1E)A\^AF M:$]LEV*YB)>RK`78LY`M;&ZL@NQ"I2NB>4(?&X`V1/&$KLVCJ!P5+\H<\@CG MU+5J/8)_G17'?^UVQ>BAVWT]*H[Q]]3_,<`_\"2)Q3WV:2S\/0L')&%8;IF$$#H1U&_PXIZLX1'J!$?610XE`LC>)Z,.R"9.Y'I*=Y> M8%RE;$HWZA`:TT,VD+H['?-\PA-1`A]XYB>8'KMID'C4"5#7%WH8"!KP#H'L M`5=?\G):)(^@,%"UTLS?>[<]]JX>.=.I\%3.CY5YP2ZX*40.K$(,,BF0SFMQ MSS[K_`L1=:WO+$V[1-)>DQL"I(N<&(*WGP/>J_4AB)ASBCAS[O5G*5-9/`)! M2:8-S/U9@VS.-"A,KDC]-E?6ZBTK.(4.DO>*RH77@(#A3@)*A MG`T;\SO!!D(HD*:8@KJEC$-Q,\$%#MJ305R$KR\,L3!1Q2)0UH M+>2Z*1TQ3D%3?^4*M)MTV)00RPU9`MJ&&(+F%19%)B<2S0R4'V2-]]#`D*9E M;G!O,`YS!:@39X,2;`N!`!\'P#^DF`@R)$E[)&-8SB4\,.4`KS06R.)4EP,` M,-!E$5+\FD^U.08BJ"/]2/;[!%,!<*OD4@U<*I#-69DBV8^,I_\L36&'BS$O MV(2NLO(0IUO.@YL68C6R+.7O$$71K*4UQ M>YOFP'(YS82IG),B92*TA-*%C1Y$")J@IU(Y-SJI]-/ZHH:%EHJ7*<%JE7@E M:C#%0-0=9#>PC*@#%%H!Y4J#I\Y`P=$(<8"[RP(=L$$T"YX_DBOF;`B%>HT& M(=3805M)Q3MH*F5F.5I'F0Y92VV_UE:E&B)VBAR.9A=N0*Z_E9!0BQQ(M%LR2T%$@(_3(MC;/T%A"1A)![G6RAXD98ZE8"+"-*@`@V>G M2@$O6BCXA7B"4!XA*C+T+"E$XL1&D9T8PTCL,HA0)W2&!TE``_BH5)@DEX,Z MQ-:)P#51`T9?+%#8($]PBQ'?,GIQU^4TQ:RAP\C#.NEV*I97[+5TX\ZZL#.( MPADIO1D+43``P=$LT.1EQ+02G#VB8M=0V?5KL50X?,8AB7LCQ0('I"1@>_1,))3C(#-HJ%) M/.61$S:EE+?7YM)LBA-S2;AHA7UA%R MG^8M<#QHAFC4&+/6\Y%.M";P?&@`$_Y%,.&)(BVFO&-J9471B]LHG)/6(X() MM;N03&[O8=I87AWOTN]:KW"BC:XCRFD7K+$!&BW(2[:%"95W::/&IRHV=_!G M96F9^RPJKZYW.V$S**)+\L]6ZF$'><^4@?\6:@<)$>Z_(NHZ8\+X/<= MSU!PH:PO415;]C4-@FQEY,T\F<(+GBW!4XUYSA@VTP7EG4!2!QD&*$%&*0,H M"K:.K-*0FNA<0H$*"">8.5N&$Y,#$P3",DRQ0"O`[U,P0=^#_XMZ+\M9@,UF M9F\=`?C:LUXIJ`SH0G:#&:>W9^Q[=MB'@@"?B@D!HV+L/'!+-GU;`7;'KB4, M%EBM]TU]I&![1\#",&DQU?*1->R>)<"NJ2T&P9:@T9`OBUQ@%@,(\/V;U";" M+L4#QN=?1-$P+BKN\'*ELFXH(,.?+%H3K0R6D]2:7G(^.0V(KCV]ZU&SJ6U2 M6TNW;>K*5,(M@N+`?BR],`7HX%,H-!]HVZ`5>4YQW8":/7N<.W.X(PE-)&0EY.,)`JT%,98$U"+XG%SH@ M[W;<86,3<0AA8_S6]0)TC)"UW:Y#%ZYTT.8!N!S7QG07)*AF2Z!>K-89/(AC M/U`*+(?.7_GYN#WQ(/)$FEH5T0/BV13X'LA@;0+I]F@90L-5:+<$_TAK'642 M#P,1'MD=3DKH\K)Q(17'D7.P(N3"U-_]M$0##TKA4T,O'HJ?-MYT:NXNY!%9 MCGAPN6X51JP\JQ"?.AUH*AXECV2U1/>]S\.QGNU6J)ML,'6^2-X@%Y8$I1?3 M6*5ZUMWS-+5_(]0!&<6:M;U_P3[Q MA_DDRD?*RMLAGZ1=4.""MC+3!J&#W6@^"`7I'D(*4;>$FONQA-U4`0=J/CU2 MTHO;AXRT29#WQP`>%+%4J?VE@EDP``XRR)P3=YF;4EO49S]0XW!]&ESMFRA% M`=40Z)\+*Y!W8)<3RD^;[MCW`&T=">ZW"S#O>9Y"4/A5<`R;OBI-O;T$%(*W MLC$/=4WQ!$G`YQF_]S&(U`4W@V&S4]>0DZ>ANXQQ(&R27[U?'(1)F#6`5'B( M'28L&3"D62JTJV(S^2_1GMU?7EVSW<-:<)3TAHF7D^2_A.]AM6;GN$+"`MO_ MY$137;>3%T0OYYX@RR8:1)3)+P*\)`PJHAQ[O+114QI[HQ:92L5=IV8R%5`B M&2OJ`&.?H^ZR>!2]L`LWW[%#9*ZS/71M*W^U&1R?0'_@\W/;HBA5Q8BTR7'8 MUVSI!GJTU)8A-]!JU+3LBGF`!VC&V.%\=FV'Y$%0+UEM^_17$V!+9RKPBDK< M-\LDK31VXX*6W9@#6LA;8+M#/'HH*MFJ9B/1-@KVCTU+(=K(]6NQM#7[YIIW M,Q=6ZT/03SE7AE,GQM19\B?Q4+S+,.INWO3;[;'@?1]6=4D<=D;HE]>[5XK= M)(7&G*0?14=@YZ(2HHO'%CCP?`(#^#XN]H9\%\%F?*@#KP[V.U$4V4X"31F` MNS.V7`='1^H>]_^7)*`&9GJ,,90KR(@8J0:U.(-,@CT6[CL5=2+HK@.V`&!='QD-VM+=2K7JH!/I11W[PX!ME14 MSMNXFSG(%KH$X$.QMU?P=M@PPU:LQ"Y[J$0-[@?1+8A>M\YJ\#"'])EH^B%H MB;E2+-ZK6U\_VH`H9QH?2.\Y-IYL%R8HOV@[_R?2$4ZKCZ=K0R5U$)B\DS[A M!NUUR=",E%;=5!0<$DH43R@":J,3B^BW;2%@Q4O@4CX!;P.2 MO6H8PZ@OIZF>@=^$CTJ;5WUT9>0SJ-EB?4:!;T6XP&S$7#4^D^2WMTC1Y;PB M1TEH)::=P\RF/D[K&T<*01^65]U<2W'C&G_0$V@]D,HF;Z;##N5/MO:+6GNA-(*1/E7IF3\:P-.4EPT=^ST6X+*]^1#;DZ?9Z-5MR8"W&^A@ M-ROJ(<-KQ::5X>MQ M;N:S+Q_*02:3RTSS]=\_W=\[V#T,/P43`)O]%$Y]%9_:K>8FZ/M4>.W0:F\^ MN[6-_I$`!)>4&?([+?A,+/9IULUT_M+.$^611^-TK4GS$"!#70 MDVVWL[E=7GRS7=H/B!4-^OVS=>B/OC7UD?^RU/K4VQNOWUS'XA5T+'Z.CGUS M#8LWE]'%-Y-1@_ZU+`3=)1&/;MK.=?W2G]PG]=[`R,FV?T@`<%%SM7.V30"V M*[]H+7U5;ZAU@07R>_C1^/@>T$?IH?_\'F0@8LGG_W"8/DSH2*`U$*$:,.$W M)D;-+_I]O]KG0>P2"*0B6^6+(C#1?BX=2SXHTDK&@ODO3\42 M5K3.GJ/`*]YIWJ0$TBH/%_Y\0NOH[N^W,T;7IANK.^QJHS]1SQN;WMS5Q<`L``00E#@``!#D!``#-5M%NVC`4 M?:92_\%C#VP23@BH$J"RBD([(;%U@E7:VV3L&V(ML2/;(?#WLT,#=!M584/L M)9:OC^\Y/D>Q?'VS3&*T`*6Y%+U:X#5J"`25C(MYK\:UQ.WV50<'M9L/EQ?7 M;S!&7Y1D&06&9BMT-_S8G^B,&T!:AB8G"NJHSQ9$.,!`)FEF0*&1$')!C&70 M=3NA7MVNI2O%YY%![P;O4;/1:.-F(VAZ*,]S#]B52@'N+C5_MB%OE?#`__9I M/*41)`1SH8V3O]ZH>5<7];&DQ0%>08GV(MP,ES#L2CAHXE;@+37;$1KR>$.3 MD!EQ)OC.G4:K%>S@7*<#+?AMRY,)0:?3\8O57;1MQ\P&OMO]RE\O_H+F+\C9 M&&O#K*S35#*&"83(C8^3T?Y#^P[AE7-DS2&LA8I"'M51X#+YL[]MZ_N[6_E4Q+3+"[*8SM_Q@I+`X(! M*WG=`?[9^0H)_I\T_)6W_004IT3<7V,@!M_]E;$KOTIA&`T<U[J,[I_QY)YPYB0'1T'\O\]#EL MF?Z7&+:*3I3"D&L:2YTI^"P-Z*_R49",V2<`&PG[AN#)/1?VI^0DWLHZ^J(_ MANO4%_\QFE[,XFFA?`;8RD]02P,$%`````@`S6:U0!2#E'00"```&%D``!4` M'`!M86)A+3(P,3(P,S,Q7V1E9BYX;6Q55`D``T)SND]"<[I/=7@+``$$)0X` M``0Y`0``[5Q;<^(V%'[>SO0_N-L'VIEU')*FW62:=KBE94I#)F1[>=H1]@'4 MVA(CR23\^TH&$RX2"-8,^3Y]!T:C-(3(ZT^]5O.7VB-/L0"/ MTX%X1@S>>;5H@H@R:-!DG`I@7IL0.D%"ML#?R7_"LW?RL_&4X>%(>-\TOO4N MSL_?^Q?GU8LS[_GY^0RB(6)9M6*?!\F9M7@[]^[_3"$23(QX0+ M!7]6D.,;GCWOT#!SP*))SVBA_O-S,U\]\JL7_F7U[(5'2T`'.%XTDZ`^4B0$ MBIWSR\OJDIVJ:4\*-HK,2:A>7U\'V:?+UK*Z2"S,EVN_"F8?KEGC+7`6Q$HQ MW\S41"QD-(9'&'CS/S\\MC?;PT0$$4Z"N4V`XOBMEX&]$=,QW+[E.!G'D#\; M,1@8<>3`%?M7BO>O56W!)V,:22`L3/O@RZ=`U&@J$*.N]D_'O*C+CV"`TE@4 MB'BS[D+QT@3A(@G>J+H`M%E%?@))'UB14%?J7<*9@UQ'N#&%!!D^'+&/31JF MTG&1_ZZ1J$4$%M,V&5"69#/>;NBJ`3^O/,-H7?<2?-E/,,'J:4?^N](HO`@@ M$41YLPI_8>YE"`(-A$]BMI8`PR$B=4R'0$#@L!=BN;`"E^M?'<5J)NR-``0_ ME-\]6C@NRWL`43CF0&(:+K=>B=4"2UEEV?/*\A@;(-[/1D7*_2%"8X6D&D`L M>/Y$<53USZOS%?7K^>.//8$$*/V?4#^&O(48]2&^K1B,@A-#E>I`6_[)=\%] M-3P1Y!KG4MI:GPN&0F&`NV:T#/6U1];8*F@YD^;5S2?55;/4B-A+N6R=CA5.%%<\RB)@LWCYI+PW4L;4S&9#_[IM:538<%(OQL7IQ&@@ M/C)PGWU4`JIG+NB9O72DF]MT[S)PO>:4GO3O3DWZ5K;+0[.)WZM#^-V,Q>1N M_6.G7:NW.^VG=JM7NV_VGKJ-WW[M=IJMQUZS===NM%OWC;\-4_3>Q1WF?7\J M],I\?[J>W\&HCV-)*5@NK5L*.*R4C;MZ;7XXX:P4AC0E@C^@J8K1GQB*3-&\ MUK0$>NA=U"OQOKCY2S;+4HC:1``#+EHO8R`<>%4S5QE-'69WNXMZ=J^+8_>> MDOG@6AINW6>(GN@CQ!)X]("8F#8HF0`36.I^3P7HR#^T)L>U.9@@PZ;LO,"1 M,7N9P>^D2S429;T(Q;R9PBHV[5"Q+NNX/GN08%#DA/ODS27.>B5W69=M[AE$ M.&A_K!\6/4'#?TX##)8TF`097U;7JR7*(X_95ROOVB>@SX_NY+661K'34B)@!?1BC.[ MVPJ'8:*)V8,39"4LT//NH#L&-DO8.TIZ@J&I$^8I&!!]3ECX_R4L/,($2`HF MH(N/'9Y,-UUQ+CVA0;E0$WQ^T+KC-8K1O`0JF%UU+D_A%SGQ,12K0[PHD5PJ MH`)/8`[=(,ZN4B70:*?CSB4^K+VI,$BS;E4"*38<A`S(:`(=RGEM@G"B/$H)9D+[&WO`VP+.BP*/NX7V`FA94.LJ.H+J([3#!9 MEHOI5P<+3(TH9O;Z$]2M-HAJ$QEO#.$^56YW!UG'X-U4J$M0ZG+=CGAX[VH< M%O!P:HZ>FK'6KRQ&3-F&BGV6Q.>CM*,'<]9%'9\[[2DH\+S-D#38>NIT>[V+ M"UT:X.(SQ_E<&"G5^`.898E%,G=`;`)EJ'%:Q=9RCC%^ASUO8H[KLA^5!S]II,?:A8ZG4`VI1S7P\KQHU]T6@GPVV0"?`V#[29G:]FR2+&;A`(/ MX`I[.:0+>F-\+V5;@L(R'T''\RU(K'>L.$QD['C:ZMI9U6)8]22CRLI1> M$=DQPA"B#,OR3:TZ98P^J]QCC106A1S7P,;MXU^24CUAEG?GH\\O'O;ZW$?,PICQEV45X M_D0_$)1&6,R_WP#G<8>Z])*_CCOX>QP/:>O(W^MX"*1M2LR?JQ_J&W/ED_\` M4$L#!!0````(`,UFM4"CTHZ470\``!6L```5`!P`;6%B82TR,#$R,#,S,5]L M86(N>&UL550)``-"<[I/0G.Z3W5X"P`!!"4.```$.0$``-5=;6_C-A+^W`+] M#[P]X-(":WN=7(ONWFX+YZUG-!<'<;:]HB@6LD0[O)5)GRCEY7[]D91DRQ(I M42*ML,`BF\CDS'#F,3E#SE#O?WQ:A^`!1A01_.%H/'QS!"#V28#PZL,1HF3P M_???OAV,CW[\X:LOW_]E,``W$0D2'P9@\0PNSG^:W-($Q1!0LHP?O0B^!I/@ MP<.\P1E9;Y(81F"*,7GP8L:!OF9_^,/7[+/-#XS?C MXR%X?'PQT>3_+FX]&__W4U]^_AVAL@3&,N?MJ1 MHG=4/+\BOAB`!DN@;,'_&N3-!OS18'P\.!D/GVA0$'2)PBV;M;?PN!)&7#MO M3D[&A7:<4DL55+ID2AB_??MV)#XMMF;D@GC;O$C]VU'Z8:DUJA%GJUAFS"_> M1R2$MW`)!,]W\?,&?GA%T7H3PE?9L_L(+N7DPB@:\?XC#%=>#`.NR;=%!O( M7>C?F^1W;**#G60N].Q/6A)[83=I=SU3:=/9DS^X8K_M"0V?8H@#&.1B5<`M)"=Z.7`=BOD/LE,)@PK\A;P>MDO8#1;#F_9]X-G24Q7\:X>]0`NM9D MC('857`3<.8\@9*`@,L%#BTS7! M&<4"C]DC=Q)N82C\,>:(/9\1S(`+!'GRYPC.+G7TB88!9K/E^B MD`5Q)6NJVW4&1R-K$VRDA,&6,DA)NP*.QK'GV-#4>_=E[]2CR)_@X!R%"9NS MKF%\12B5+6NJED;+5@-[$P@(TH`YER!(B0,,F1?$R+N"`@T%%%<<+0-T1\+$ M]Z,$!E,<0V:T^.)I`S&%4B@HFQIAH4D`$S!DM`'*B`.847<)"TT**()!SP3] M^1<32F'<$#GMMS'V*J0L[<5+GB#O"CYJ!UWV)&H4?5@GXA:N$`_C<7SMKC9(KP0;.Q=W5;#X_/I9MR6P_,]MD*;,P07X`RDC.EBGU$YE;46UC-.TK M61KMFO,3Z@&`S-#,0=@(RG76[DW@S5ZZC`7)^U[$E*,O+F8-$.EO4>."*%8R M\9'Q\E5D8`I85\PL&UMY;:IJ[U`+4A9H7R+J>^%OT(O4:Y*RJ=&RU"2`D=FS M[9"4..#4G5R=FG107*#TK'`HN$S8VACP]?$R]%82C.Q_;@0,*2NC?=2<(.`4 M7;*_=*A%H]>HM;LW,HM6'D;_$TG/9P13$J)`_#'!P0TS#F,G_IPM+Q'VL(^\ M<)>H-E;D1EDD;.3WV!V<4:Q,8@AB`CYB+PD0WS01D0=:@RUGL&/M"BSMZ[#H MP1P"(?VY/;?P`>($JK(0MA\;NS]E1B8PS&BY@B_5$,N>D%R9W2<]<4XRCXG_ M^9Z$;*CT'"Z1CR#VGV716&USHPE*1Q#S`Z$B@[]Y&T+_`79\7,&"KCJ*,XB^ M87H,A\AZ3;`02FP@JT*CMB91:EYX.79IDGM9OO& MHG#FDHF6D<>KB1^C!Y&Z6Q.+:7]^:RE5&KD4MI-HCQ,]J1+:%`-N"9;\L4FP,69241?`\TE1R^]=[*7WM>`)GE;N[F7A\!0FGWI''QJQUV;AFD'-"WC M)\8W\L(I#N#3S_!9'3B5VMF(F.2L;81**64@2`-&VQ6,-`Y>$AS5*;[/S=A= MP=I=Y&'*O4#F>Y\CZH>$,H_\#C[%ITR"S\K]6GT*%K9T6XMK'&#]?0B*=8[\ M&>4G$IDLX,:E4D<#157WCCL:MC_T)KC&L24&B@#J4'[W<.M*?8CZ%%X#M/_ISCC06^\9X]]65D0D%7+ MU-4T=2)C%+:9"&Z6?)KR`U\'&>=O`,(L\D^9@TW*701_7E8WY5J>JJG^BI&B MN>7[F^M^@A@RAX%+%*P1%A4=,7J`]2G13;V,YT%-L4Q0F[%(4;G'Q!5,ME1& M>8)L922#,L_TWD&Q&98#VPOI>0+W+RZ0UGUJ]S4K!&TKHE%&4\8LW0C=SGF, M'P@2D73B[&T6K?6T5T#:S98]'M40O"88\I+W;C%)"P+F1SNMA37V$+\=[@@-92^/SH!KV%FH/%CGUPU0@&`J_ M*5U_:6T<+W%V5:.+\E%5(Y!LADKYYJ38J:S+1]7N:CDDJA?0Y$OP=<[L&Y#' M03P,*01!(C/YUYXXZ&`2>=M4.R%BI5=U=K\6*->##,_ M,R?-'$D4"*BEU%W!F*82*J<<.L;H$4G[L3OS%0)56"QM:HZA&@$,K[#9WY\9 M@)C3=@X^->.O8*?1`MT7NZOIY'1Z-;V;7LPGU^?SN]G9S_^<79U?W,[/+RZG M9].+Z[/?:A:\5MV-%KTN@IH`J<`/,(:@R#'/;]XR=@5=71557`2[F_30I>R[ M2K1+]D26X:IJ::6<7<'>2D%[L6Y04'<%41H*D!6UUQK`4GIB5K!33%*K\\WU M^]I+4-01T6:&XC+G]Z?(4-31CC)%4=^"W>&VJP0KYMK68*RA@Q&P](0Q0=/^ MRP%V/%P"D)X6BJAI8Q/#:J]"$MP$!RUKO_0ZFU>"M1+2O"ZLP$Z<&_RYZL1: M*:M2-=;!I(=-=1.WXIZQ[\.*1.I$M_U6%M+/!TDPYNOK[@*ZCY1?G#K%#Y#N5P*H#I+T"9@?)+46UMC+2JBX&)?]RW@4 M7"Q7D-==/95SI([&[+Z`YDDC?'OL]'E*:<(/7F?+0F6E;.G4ZF:T:+81S&A. MR_BD&Y^+9X`R5MP9\QVLD6VKG.+RV-YL?197TYBOU[F,#;4#RN86BJWK!3$K MNF:TA4.6)ZTY$R?J#K]:@ZUC"`N;#WPN/'V6U,BI3KV;>MG9<&@6R])6@U@* MV00EJX=T!40M-2/=9M"U6*].VA2SM0#R=QI,'CP4B@,!4I@VLP!#%/:I/;56 M5&RX:UW$-DK^N;@#_!Y>5_!HJ`J)?];=A'W7X*D.%M,/+579V=NQF#B5TR`? MI;R([B6.8]+L&[T#F6);BT`$G]<@Y01F[KW9M)UB),6:VN8R\,3OF8)Y=A;S MU.2IIOL-S/QK*3,C5UI03'.;W+DM6#W6/>>X1K-])L+])Z&Q.-3A>?A\5"B$ M>TX1\X4D&UCZ5]HB8Q&Z3-8B[;HFWTNSH\U[ZQJ$,T%4]5W`S*,`E',#7LK.&<^LO69J MKKW3LEM_\]L-HP6C"`:-%SS+6AK/7S7L3="U)>O6*;;&J,LS4Z/6#^M7W22+ M$/F7(?'*4Y*\C07_2<+2@L^44@6"K"MPJ!USU3-2ZMED,0IY+L3\'C84FRH: M&BXV=[^2R^8*A)K&WI3"9J^025IZ4%O)5-_# ML)1)2QRS6J9*F4FPY>14%*NIC/V2IA;&Z6]JV59:W?%D),7$4FID/*W(F5HI M@P._"YI_N(*6^B&7YY(Z1??[IBJ4GF:Q>>V,B$M-&5K9$JA_1UE+(E;> M:./-W.^&H,!9+&A[O%W#83QO!8LO)%;"UTTMQE6QK+4O7$DAJI+2O):CM M:^]:`AT1;5Y+(*N9<\H':ZT=Y;4$^A;L\\4%L8^GZP3\85( MO4=59H9&1PNO*=`5SO!:J)QJ%@Y8_8 MCX5'(7OR?U!+`P04````"`#-9K5`_EK:[3@*```9?0``%0`<`&UA8F$M,C`Q M,C`S,S%?<')E+GAM;%54"0`#0G.Z3T)SND]U>`L``00E#@``!#D!``#M75MS MXC@6?NZIFO_`]CPP6]6$D$SO=E*=G2)<>JEF0RK0,SM/7<(^@+:-Q$@R"?OK M5[)Q,$8R-K'!SO9++O:1=,[W'=V.CN#CKT]SI[($QC$E-]7&V7FU`L2B-B;3 MFRKFM/;AP_NK6J/ZZS]^_.'C7VJURCVCMFN!71FO*IWVI^8#=[&`"J<3\8@8 MO*LT[24B2J!%YPM7`*OT"*%+)&0+_)W\QSI[)]\M5@Q/9Z+R<^NOE8OS\P^U MB_/&Q5GE\?'Q#.PI8EZU9Q:=5VHUU;:#R;=K]6.,.%2DUH3?O)T)L;BNUU6A MIS%SSBB;UF5EE_5`\.V//[QYXPE?/W&\5>#Q,A!OU/_]K_[0FL$N!U2=(*=YV;F:(P4"'6% MSOGE92,DIVI*"<%.D34(C:NKJ[KW-BPMJ[/%LWBX]O=U_V5$&L>H\PRL)/.- MSR:C#CS`I*)^?WGHF8VN*XDZMMG7-K7<.1`1_&X2NT,$%JL>F5`V]SAZ6_$L MN1:K!=R\Y7B^<"!X-F,PN7FK&J@%E2OT?TI<=WVC_H(!EV+>\[Y\L-4L/`D@ M-MA!P\J"S`Q4.JR5<*@5;K?J*$>EK!JVM[IKK_2QKW%--,=<,&2)H!X'C<&Y MJ28N5D^K8MC).%AG4[JLVX`50@WUAU*_43MOK+O+3_+15[_Y!YABU2H1=V@. M$86-8F$%PT0VV;:RB%E!E?)/C\6JTYXMCXWP/#%-I M@]U&(@[P;;F2(A\Q5D_!Y;$H:$J5;*56UT%3#?3;[TL&><0X/=2_'`MJ7^V6 M5(#YPA5I/JWV:N6_$%2H9/TE@T#/U]^,R=>^. M'6QU'8JBBV>]3"EYV#)2#_N'X\+>Q0ZPENRP4\K,L\6V5"FACQBJ!__JR*.3 M/W@^P((R(;OB4.+H!&;DPR9>2$Z/Q!FZ.OJ?>+/BZ\HFN MAY@D2\:'T6`#$T?;6F\KYF_[DW$1EBTU&UM&&_AXWG]_K.\8V96V*T,+OB^`('CR)=LKUXZ]J*0->$!2-G>C>WR!TPFX8 MC[+J>";#<@JC9X"\]'GHR3^C8V&,X(D8B'<:+?HAXPK'0)-SZ46&KFH0*@KR M.TX31C]J6$&17V^K$A$0E2T1#SMFYG32=#@=+<1G!O2]5Z4`VS\[?5[HUYGV+QK#T>#UN=_#OKM MSL.PW>GV6KW.7>N/F&5MJN*%1CX]&#F='AWN_7V,QMC!`D/"23:F0*&Y2F)P M3B=&+QB;+(NZ1/![M%+KYQ%#MFGGI14M!2-Z(S,\1M*/8K)9YH+=(P(D,J+S MM`#"@3>$XO-C-Q!F9YDJ3O&EZ^R8PZLF+>A@GVHL6KN$#NOA*%!CN1 MR7F=&AWN_/>R+I`^87NZ_X8=%YT@9K3)THJC84>L%!SL M&F<@X,79FB_81=@V]M6Y1UBN!5MH@8723;^1,$B7@@ZCJ0963KCS?@"!I"EV M!S&"R93+M84[=[TEA3_$FF;K!`5+P542``RT';0EU\_F(RK]PS"_::;R6/%" MP[[?6`/8&>ZYO?9#JS:YI$X)?;+"Y2`B(1`&6JY.E@'R;!X?3`8+8/Y=WEQ2 M00Q-G30GQ*!35IL+7>6Q>XO8`J=.62A'LD@RU+\GC7Q/&DFUP%L"<<&$^_/K MHJ"]9[$6&%,XG%N4"S6!!L'M/0=81O%2\&`VMG"Y(I_DS,F0H\*F]AP3[ZJZ MP$M8JVZ@9U^I4K"TU_3")9]$3H@,Y$2E2D'&CFF%2T&)=NJ$(UU;'J:LI-(6'@Y-[>DS$ MLQ+TFO)UEP29*B<-7JI$\*Y#'_./76Y:*DSHU*?6B)R@J6T^DAN?85!5ST$78>:EV,E]&[`EEBO:C9.$$2'I)N>V++E M(6,_##E]VN2+#O)TBT>-%>8SO*05%)K(0P#)_U+AEFMU,9'KR,-Z6&S90A.3 M$H8L+Q7J.9&N85E@>[J$;S3>4L;HH\K+UY"1H%#A64AB>/Z7"94O^-E"0G5/ MG3<8.L.^4H4G()'I65XL-#`P0V2J%NM2G4LMV-L"Q<:Z7V417-#L^P@8-?75].J4JC#AR6?)3H?8>WG9 MEBD%(Q&S8B[Y'<2%K#[$1!Y'U6W,+8=REWF?[,!']`M!KHW%^B,[<+`\4+>V M@J/;@[_0[)"V\CZN/DBI;/K%@$T1P?_U[&E1PJF#;=_%B7T?LG4PT>@0MU3- MJ.)3[:&0D&R$[\&8]DJ[@B>\PI,MFUM[*`T@A3L"[^,_72S[S6K3H3Y1.55) M*"Q@1'4N`XU)2KY*7A-!5KAC2I5BQ0>3=78X8 M(ES:HH:1C=^-Y/1Y*S7X9B`S30VODN94$!;N?L<=)7-*0'T9R6'\IZC@5=*? M!L#"W2Y1Y^38SWF00$A@U#`%TGQ(X0$I*WF57I`6R#W'K.;]W/J-^J&^,EL^ M^1]02P,$%`````@`S6:U0),&BA1`L``00E#@``!#D!``#M65N3VC84?DYG^A_4 M?7$[$V-@NYWL#B3#`ILRI<`LI-,^980M@R:V1"49EO[Z'LDVF+LAFXW;R;ZL M;9W+]^E(1^>(VKNG,$!S(B3EK&Y52F4+$>9RC[))W:*2VV_>W-S:%>O=V^^_ MJ_U@VV@@N!>YQ$/C)6JWWC<>940509+[:H$%>8T:WAPS+=#DX2Q21*`.8WR. M%7B0K^'%+;V&L=E2T,E4H1^;/Z%JN?S&KI8KU1):+!8EXDVP,&9++@^1;6O? MTIV2$".`R^2=1VC=FBHUNW.D2>,JET(+/RGMJ<]D3XQHD'4]%(VA.,9RM9 M'\NQD4T&LB&"V+ZJ85@ARJP0_0KOLQEE/CR"A)Q'VE/R+BJ.=L^LJXC2;P^>VN>MW-!HIF('-+:W&[Y=+96P1ZEY%,: MR<^-;HN[D9Z;]'^#>6VFJ%IV(/F*T"!9QS.7]+$(5G0$4^WL(V8>BDVAC*UO M(3JUB>YQH$_HX900E7?C;>H<"U?UH@V7V$>Q@V\QU!N'2C?@,A*DQQ61(_Z! MXDW^RT+;+U)[M2A1ZF]"2A!V0[W=^1GLHY%X"GA*,+4(=%)K3: M_:UV7_DEE_MM_<]!P%GO#.*>WM6AP1*IE_L M=1=[",*QQA?EAK)]N:$?C$2.T^N-1"C`;13T&)82D2ZX]=W`W>0$"CW M]&:J6UX4)P<+F3;(BB6D$I1-.I!%M)2%\!B^8%>E=B#?63X-/G8[C?M.MS/J MM(>-7FLXZC=_^[7?;;4?AZWV0Z?9:?>:?S4270O)"!ZIBK2_]X)'L]0=G$QA MS+1NG6?R9>D>JY#/I)G/U,O2VW]`G4GLE)&7I72/)75ACELTB*#\&1`QG&)! M&B&/`.&9U/(:>UF*JR[[0?`PF7$V:;B*SJF^-3B39'YS7X;F.G*9?J:R]KH] M#6EH]DN?H)R'PC@V#?C)F*I]Q.+37VWR"CE49U@L=YDU7!?,QU4^D:K]-"-, M$EE)N1P>+R2;^&^U1MS\<5JLIC\R'KQH& MZ&D$P9*T2/R_PYJ1$/KDE#)/9LBO_U5I;J3=#IO#QM](NR=YGF&@.$236XC+ MB1XW4,1\V>/I`NQ2/*:!P=Q?$&\S^S4YA%`H"H#T+UZL7L2Y&$'7'AQ( MF"GAXS*%996)#AQR>3CFU"CF\;%5&O>(ZG*Y+FD.#O\GV!RB45C\:NS4-5-&F"1W@I4:0UM7$V^DN+M,MYCRL2H$/4D=O3[=:V:D:CHD6 ME^5[PC1@#7U?R9-E>5+T95B>>6AJY&WF]?V!L7&]06EKH+`$[LF$,@;SO9_& MWN&"KKDI9A/=*P'L#(FMK\7$#NG<=8EG^H-L37S/A>`+F'Z9\LDC^56;I;Z8 M8$;_,1I0TDL>4"^^(F;>(/,;7=_?\V/QR4[JN:SGF**:$_\0`H__`E!+`0(> M`Q0````(`,UFM4"AR=C@I!0``(Y9```1`!@```````$```"D@0````!M86)A M+3(P,3(P,S,Q+GAM;%54!0`#0G.Z3W5X"P`!!"4.```$.0$``%!+`0(>`Q0` M```(`,UFM4#"G6/C-`(``.T)```5`!@```````$```"D@>\4``!M86)A+3(P M,3(P,S,Q7V-A;"YX;6Q55`4``T)SND]U>`L``00E#@``!#D!``!02P$"'@,4 M````"`#-9K5`%(.4=!`(```860``%0`8```````!````I(%R%P``;6%B82TR M,#$R,#,S,5]D968N>&UL550%``-"<[I/=7@+``$$)0X```0Y`0``4$L!`AX# M%`````@`S6:U0*/2CI1=#P``%:P``!4`&````````0```*2!T1\``&UA8F$M M,C`Q,C`S,S%?;&%B+GAM;%54!0`#0G.Z3W5X"P`!!"4.```$.0$``%!+`0(> M`Q0````(`,UFM4#^6MKM.`H``!E]```5`!@```````$```"D@7TO``!M86)A M+3(P,3(P,S,Q7W!R92YX;6Q55`4``T)SND]U>`L``00E#@``!#D!``!02P$" M'@,4````"`#-9K5`DP:*%%P&``";*@``$0`8```````!````I($$.@``;6%B M82TR,#$R,#,S,2YX`L``00E#@``!#D!``!02P4&```` /``8`!@`:`@``JT`````` ` end XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } EXCEL 12 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\X-C0W965A9%]A,CDW7S1D,#)?8C%E.%\R9F9E M8C8V9F4Q.3DB#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I7;W)K#I3='EL97-H965T M($A2968],T0B5V]R:W-H965T3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\X-C0W965A9%]A,CDW7S1D,#)?8C%E M.%\R9F9E8C8V9F4Q.3D-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO M.#8T-V5E861?83(Y-U\T9#`R7V(Q93A?,F9F96(V-F9E,3DY+U=O'0O:'1M;#L@8VAA M'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^36%R(#,Q+`T*"0DR,#$R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^9F%L2!#96YT3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^,#`P M,#@U-CDX-#QS<&%N/CPO'0^+2TQ,BTS,3QS<&%N/CPO2!0=6)L:6,@1FQO870\ M+W1D/@T*("`@("`@("`\=&0@8VQA2!#=7)R96YT M(%)E<&]R=&EN9R!3=&%T=7,\+W1D/@T*("`@("`@("`\=&0@8VQA2!&:6QE'0^,C`Q,CQS<&%N/CPO'0^43$\'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA3PO=&0^#0H@("`@("`@(#QT9"!C;&%S3PO=&0^#0H@("`@("`@(#QT9"!C M;&%SF5D.R`Q+#`X."PW-#`@:7-S=65D(&%N9"!O=71S=&%N9&EN M9R!A="!-87)C:"`S,2P@,C`Q,B!A;F0@1&5C96UB97(@,S$L(#(P,3`\+W1D M/@T*("`@("`@/"]T7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA'!E;G-E7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA2!R96QA=&5D('!A'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA3PO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/"$M+65G>"TM/CQP/CQB/DYO=&4@,2X@5&AE($-O;7!A M;GD\+V(^/"]P/B`\<#Y!;65R:6-A;B!":6]G96YE=&EC(%-C:65N8V5S+"!) M;F,N("AT:&4@(D-O;7!A;GDB+"`F(S$T-SM7928C,30X.R!O2!W87,@96YG86=E9"!I;B!T:&4@2!U;F1E2!#;W5R="!%87-T M97)N($1I2!E;65R9V5D(&9R;VT@0F%N:W)U<'1C>2!#;W5R="X\ M+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`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` end XML 13 R2.htm IDEA: XBRL DOCUMENT v2.4.0.6
American Biogenetic Sciences, Inc. - Balance Sheets (USD $)
Mar. 31, 2012
Dec. 31, 2010
Cash $ 0 $ 0
Total current assets 0 0
Total Assets 0 0
Accounts payable - trade 10,068 7,568
Accrued interest expenses 22,800 20,520
Convertible note, related party 76,000 76,000
Advances from and accruals due to related party 143,113 129,113
Total current liabilities 251,981 233,201
Preferred stock    [1]    [1]
Common stock 109 [2] 109 [2]
Additional paid in capital 46,191 46,191
Accumulated deficit (298,281) (279,501)
Total Stockholders' Deficiency (251,981) (233,201)
Total Liabilities and Stockholders' Deficiency $ 0 $ 0
[1] $0.0001 par value; 10,000,000 shares authorized; none issued
[2] $0.0001 par value; 100,000,000 shares authorized; 1,088,740 issued and outstanding at March 31, 2012 and December 31, 2010
XML 14 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.1.0.1 * */ var moreDialog = null; var Show = { Default:'raw', more:function( obj ){ var bClosed = false; if( moreDialog != null ) { try { bClosed = moreDialog.closed; } catch(e) { //Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control // that somtimes causes it to throw when checking the closed property on a child window that has been //closed. So if the exception occurs we assume the window is closed and move on from there. bClosed = true; } if( !bClosed ){ moreDialog.close(); } } obj = obj.parentNode.getElementsByTagName( 'pre' )[0]; var hasHtmlTag = false; var objHtml = ''; var raw = ''; //Check for raw HTML var nodes = obj.getElementsByTagName( '*' ); if( nodes.length ){ objHtml = obj.innerHTML; }else{ if( obj.innerText ){ raw = obj.innerText; }else{ raw = obj.textContent; } var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g ); if( matches && matches.length ){ objHtml = raw; //If there is an html node it will be 1st or 2nd, // but we can check a little further. var n = Math.min( 5, matches.length ); for( var i = 0; i < n; i++ ){ var el = matches[ i ].toString().toLowerCase(); if( el.indexOf( '= 0 ){ hasHtmlTag = true; break; } } } } if( objHtml.length ){ var html = ''; if( hasHtmlTag ){ html = objHtml; }else{ html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ objHtml + "\n"+''+ "\n"+''; } moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write( html ); moreDialog.document.close(); if( !hasHtmlTag ){ moreDialog.document.body.style.margin = '0.5em'; } } else { //default view logic var lines = raw.split( "\n" ); var longest = 0; if( lines.length > 0 ){ for( var p = 0; p < lines.length; p++ ){ longest = Math.max( longest, lines[p].length ); } } //Decide on the default view this.Default = longest < 120 ? 'raw' : 'formatted'; //Build formatted view var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ; var formatted = ''; if( text.length > 0 ){ if( text.length == 1 ){ text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ; formatted = "

"+ text.join( "

\n" ) +"

"; }else{ for( var p = 0; p < text.length; p++ ){ formatted += "

" + text[p] + "

\n"; } } }else{ formatted = '

' + raw + '

'; } html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+'
'+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+'
'+ "\n"+' '+ "\n"+'
'+ "\n"+' '+ "\n"+'
'+ "\n"+''+ "\n"+''; moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write(html); moreDialog.document.close(); this.toggle( moreDialog ); } moreDialog.document.title = 'Report Preview Details'; }, toggle:function( win, domLink ){ var domId = this.Default; var doc = win.document; var domEl = doc.getElementById( domId ); domEl.style.display = 'block'; this.Default = domId == 'raw' ? 'formatted' : 'raw'; if( domLink ){ domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed'; } var domElOpposite = doc.getElementById( this.Default ); domElOpposite.style.display = 'none'; }, LastAR : null, showAR : function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }, toggleNext : function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }, hideAR : function(){ Show.LastAR.style.display = 'none'; } } XML 15 R3.htm IDEA: XBRL DOCUMENT v2.4.0.6
American Biogenetic Sciences, Inc. - Statements of Operations (USD $)
 3 Months Ended
Mar. 31, 2012
Mar. 31, 2011
Revenue $ 0 $ 0
General and administrative 16,500 23,102
Interest expenses 2,280 2,280
Total costs and expenses 18,780 25,382
NET LOSS (18,780) (25,382)
Basic and diluted net loss (0.02) (0.02)
Basic and diluted $ 1,088,740 $ 1,088,740
XML 16 R1.htm IDEA: XBRL DOCUMENT v2.4.0.6
Document and Entity Information (USD $)
 3 Months Ended
Mar. 31, 2012
Document and Entity Information  
Entity Registrant Name American Biogenetic Sciences Inc.
Document Type 10-Q
Document Period End Date Mar. 31, 2012
Amendment Flag false
Entity Central Index Key 0000856984
Current Fiscal Year End Date --12-31
Entity Common Stock, Shares Outstanding 1,088,740
Entity Public Float $ 65,748
Entity Filer Category Smaller Reporting Company
Entity Current Reporting Status Yes
Entity Voluntary Filers No
Entity Well-known Seasoned Issuer No
Document Fiscal Year Focus 2012
Document Fiscal Period Focus Q1
XML 17 R4.htm IDEA: XBRL DOCUMENT v2.4.0.6
American Biogenetic Sciences, Inc. - Statements of Cash Flows (USD $)
 3 Months Ended
Mar. 31, 2012
Mar. 31, 2011
Net loss $ (18,780) $ (25,382)
Expenses paid by issuance of common stock 0 0
Fair value of services provided by related parties 14,000 19,000
Increase (decrease) in accounts payable and accrued expenses 4,780 6,382
Cash flows used by operating activities 0 0
Cash used in investing activities 0 0
Procceds from related party borrowings 0 0
Cash generated by financing activities 0 0
Change in cash 0 0
Cash - beginning of period 0 0
Cash - end of period $ 0 $ 0
XML 18 R5.htm IDEA: XBRL DOCUMENT v2.4.0.6
Notes to Unaudited Interim Financial Statements
 3 Months Ended
Mar. 31, 2012
Note to Unaudited Interim Financial Statements  
Note 1. The Company

Note 1. The Company

American Biogenetic Sciences, Inc. (the "Company", “We” or "ABS") was incorporated in Delaware on September 1, 1983. Prior to ceasing its operations in 2002, the Company was engaged in the research, development and production of bio-pharmaceutical products. On September 19, 2002, the Registrant filed for bankruptcy under the U.S. Bankruptcy Code in the U.S. Bankruptcy Court Eastern District of New York. On November 4, 2005, the Company emerged from Bankruptcy Court.
Note 2. Going Concern

Note 2. Going Concern

The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred losses, has negative operational cash flows and has no revenues. The future of the Company is dependent upon Management success in its efforts and limited resources to pursue and effect a business combination. These conditions raise substantial doubt about the Company's ability to continue as a going concern. These financial statements do not include any adjustments that might arise from this uncertainty.
Note 3. Basis of Presentation

Note 3. Basis of Presentation

The Financial Statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America. In the opinion of management, the accompanying unaudited financial statements include all adjustments, consisting of only normal recurring accruals, necessary for a fair statement of financial position, results of operations, and cash flows. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the financial statements and the accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2011. The accounting policies are described in the “Notes to the Financial Statements” in the 2011 Annual Report on Form 10-K and updated, as necessary, in this Form 10-Q. The year-end balance sheet data presented for comparative purposes was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States. The results of operations for the three months ended March 31, 2012 are not necessarily indicative of the operating results for the full year or for any other subsequent interim period.

Accounting Policies

Use of Estimates: The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from the estimates.

Cash and Cash Equivalents: For financial statement presentation purposes, the Company considers those short-term, highly liquid investments with original maturities of three months or less to be cash or cash equivalents.

Fair Value of Financial Instruments: ASC # 825, "Disclosures about Fair Value of Financial Instruments," requires disclosure of fair value information about financial instruments. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of March 31, 2012. These financial instruments include accounts payable and accrued expenses. Fair values were assumed to approximate carrying values for these financial instruments since they are short-term in nature and their carrying amounts approximate fair values.

Earnings per Common Share: Basic net loss per share is computed using the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed using the weighted average number of common and dilutive equivalent shares outstanding during the period. Dilutive common equivalent shares consist of options to purchase common stock (only if those options are exercisable and at prices below the average share price for the period) and shares issuable upon the conversion of issued and outstanding preferred stock. Due to the net losses reported, dilutive common equivalent shares were excluded from the computation of diluted loss per share, as inclusion would be anti-dilutive for the periods presented. There were no common equivalent shares required to be added to the basic weighted average shares outstanding to arrive at diluted weighted average shares outstanding as of March 31, 2012 or 2011.

Income Taxes: The Company accounts for income taxes in accordance with ASC # 740, "Accounting for Income Taxes," which requires recognition of estimated income taxes payable or refundable on income tax returns for the current year and for the estimated future tax effect attributable to temporary differences and carry-forwards. Measurement of deferred income tax is based on enacted tax laws including tax rates, with the measurement of deferred income tax assets being reduced by available tax benefits not expected to be realized.

FIN 48 requires that the Company recognize in its financial statements the impact of a tax position, if that position is more likely than not of being sustained on audit, based on the technical merits of the position. Management of the Company is not aware of any additional needed liability for unrecognized tax benefits at March 31, 2012 and 2011.

Impact of recently issued accounting standards

There were no new accounting pronouncements that had a significant impact on the Company’s operating results or financial position.

Note 4. Convertible Notes to Related Party

Note 4. Convertible Notes to Related Party

In October 2009, we issued a convertible promissory note in the amount of $76,000. The note bears interests of 12% per annum until paid or converted. Interest is payable upon the maturity date. The conversion rate is $0.001 per share. The note was issued in consideration of cash advances made and for services provided to the Company by our President.

In accordance Accounting Standard Codification ( “ASC # 815”), Accounting for Derivative Instruments and Hedging Activities, we evaluated the holder’s non-detachable conversion right provision and liquidated damages clause, contained in the terms governing the note to determine whether the features qualify as an embedded derivative instruments at issuance. Such non-detachable conversion right provision and liquidated damages clause did not need to be accounted as derivative financial instruments.

Note 5. Related Party Transactions

Note 5. Related Party Transactions

Fair value of services: Our President provides services to the Company, which services are accrued and are valued at $2,000 per month. The total of these accrued expenses for the period ended March 31, 2012 was $6,000 and is reflected in the statement of operations as general and administrative expenses.

An entity controlled by the Company’s President provided office space to the Company valued at $1,000 per month. The total of $3,000 during the three months ended March 31, 2012 was recorded as accrued expenses and is reflected in the statement of operations as general and administrative expenses.

An entity controlled by the Company’s President provided corporate securities compliance services to the Company valued at $5,000 during the period ended March 31, 2012, which was recorded as accrued expenses and is reflected in the statement of operations as general and administrative expenses.

Due Related Parties: Amounts due to related parties consist of fair value of services provided by our President, accrued office space expenses, corporate regulatory compliance expenses and cash advances received from our President and control shareholder. Such items due totaled $143,113 at March 31, 2012 and $129,113 at December 31, 2011.
Note 6. Commitments and Contingencies

Note 6. Commitments and Contingencies

There are no pending or threatened legal proceedings as of March 31, 2012. The Company has no non-cancellable operating leases.
XML 19 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.6 Html 6 52 1 true 0 0 false 2 false false R1.htm 000010 - Document - Document and Entity Information Sheet http://maba.com/20120331/role/idr_DocumentDocumentAndEntityInformation Document and Entity Information true false R2.htm 000020 - Statement - American Biogenetic Sciences, Inc. - Balance Sheets Sheet http://maba.com/20120331/role/idr_AmericanBiogeneticSciencesIncBalanceSheets American Biogenetic Sciences, Inc. - Balance Sheets false false R3.htm 000030 - Statement - American Biogenetic Sciences, Inc. - Statements of Operations Sheet http://maba.com/20120331/role/idr_AmericanBiogeneticSciencesIncStatementsOfOperations American Biogenetic Sciences, Inc. - Statements of Operations false false R4.htm 000040 - Statement - American Biogenetic Sciences, Inc. - Statements of Cash Flows Sheet http://maba.com/20120331/role/idr_AmericanBiogeneticSciencesIncStatementsOfCashFlows American Biogenetic Sciences, Inc. - Statements of Cash Flows false false R5.htm 000050 - Disclosure - Notes to Unaudited Interim Financial Statements Notes http://maba.com/20120331/role/idr_DisclosureNotesToUnauditedInterimFinancialStatements Notes to Unaudited Interim Financial Statements false false All Reports Book All Reports Process Flow-Through: 000020 - Statement - American Biogenetic Sciences, Inc. - Balance Sheets Process Flow-Through: 000030 - Statement - American Biogenetic Sciences, Inc. - Statements of Operations Process Flow-Through: 000040 - Statement - American Biogenetic Sciences, Inc. - Statements of Cash Flows maba-20120331.xml maba-20120331.xsd maba-20120331_cal.xml maba-20120331_def.xml maba-20120331_lab.xml maba-20120331_pre.xml true true